An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency-Reference-Cited by-同舟云学术

An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency

Published:2021-04-29 Issue:4 Volume:27 Page:690-698
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Martin Erika J.¹,Nolte Melinda E.²,Kuhn Janice²^ORCID,Schmidt Nicole³,Pfaff Nils⁴,Brophy Donald F.¹^ORCID

Affiliation:

1. Coagulation Advancement Laboratory Department of Pharmacotherapy & Outcomes Sciences Virginia Commonwealth University (VCU) School of Pharmacy Richmond VA USA

2. Department of Internal Medicine Division of Hematology/Oncology VCU School of Medicine Richmond VA USA

3. Research & Development, Pharmaceuticals Bayer AG Berlin Germany

4. Research & Development, Pharmaceuticals Bayer AG Wuppertal Germany

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14314

Reference21 articles.

1. Current progress and future direction in the treatment for hemophilia

2. Targeting TFPI for hemophilia treatment

3. Heparin Induces Synthesis and Secretion of Tissue Factor Pathway Inhibitor from Endothelial Cells In Vitro

4. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets

5. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases;Frontiers in Cardiovascular Medicine;2022-11-10

2. Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review;Journal of Thrombosis and Haemostasis;2022-04

3. Basic and clinical aspects of anti-tissue factor pathway inhibitor (TFPI);Japanese Journal of Thrombosis and Hemostasis;2022